用于治疗骨质疏松症的双膦酸盐类药物。 - Suppr

Suppr

超能文献

Bisphosphonates for osteoporosis.

作者信息

Favus Murray J

机构信息

Department of Medicine, University of Chicago, Chicago, IL 60637, USA.

出版信息

N Engl J Med. 2010 Nov 18;363(21):2027-35. doi: 10.1056/NEJMct1004903.

DOI:10.1056/NEJMct1004903

PMID:21083387

Abstract

摘要

相似文献

Bisphosphonates for osteoporosis.

N Engl J Med. 2010 Nov 18;363(21):2027-35. doi: 10.1056/NEJMct1004903.

[New bone density conservation agents for osteoporosis under research and development: Minodronic acid].

Nihon Rinsho. 2007 Nov 28;65 Suppl 9:417-20.

Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis.

Curr Med Res Opin. 2010 Nov;26(11):2553-63. doi: 10.1185/03007995.2010.519658. Epub 2010 Sep 21.

Persistence with bisphosphonate therapy in older people.

J Am Geriatr Soc. 2006 Jun;54(6):1015-6. doi: 10.1111/j.1532-5415.2006.00758.x.

In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?

J Okla State Med Assoc. 2010 Aug;103(8):374-5.

Bisphosphonates for osteoporosis--where do we go from here?

N Engl J Med. 2012 May 31;366(22):2048-51. doi: 10.1056/NEJMp1202619. Epub 2012 May 9.

[Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].

Clin Calcium. 2007 Jul;17(7):1090-6.

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

Curr Med Res Opin. 2006 May;22(5):919-28. doi: 10.1185/030079906X100276.

Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.

Prescrire Int. 2009 Dec;18(104):247.

Emerging issues with bisphosphonates.

Rheum Dis Clin North Am. 2006 Nov;32(4):691-702, vi. doi: 10.1016/j.rdc.2006.08.002.

引用本文的文献

Long-term bisphosphonate use and femoral morphological changes in osteoporosis patients: a retrospective cohort study.

Eur J Med Res. 2025 Jul 1;30(1):536. doi: 10.1186/s40001-025-02764-4.

Effect of recombinant human parathyroid hormone and zoledronic acid on osteoblast gene expression using multifaceted approach: An in vitro study.

Indian J Pharmacol. 2025 Mar 1;57(2):69-76. doi: 10.4103/ijp.ijp_582_23. Epub 2025 Jun 13.

Sympathetic cholinergic nerve fibres promote BMSC differentiation into osteoblasts via NRTN secretion: a potential treatment for osteoporosis.

J Orthop Surg Res. 2025 Jun 5;20(1):571. doi: 10.1186/s13018-025-05944-4.

Molecular mechanisms and treatment strategies for estrogen deficiency-related and glucocorticoid-induced osteoporosis: a comprehensive review.

Inflammopharmacology. 2025 Apr 28. doi: 10.1007/s10787-025-01749-3.

Optimizing bone health with bisphosphonate therapies in pediatric osteogenesis imperfecta: a network meta-analysis of randomized trials.

Arch Osteoporos. 2025 Mar 6;20(1):33. doi: 10.1007/s11657-025-01515-6.

Towards Optimal Automated Ga-Radiolabeling Conditions of the DOTA-Bisphosphonate BPAMD Without Pre-Purification of the Generator Eluate.

J Labelled Comp Radiopharm. 2024 Dec;67(14):441-453. doi: 10.1002/jlcr.4128. Epub 2024 Nov 20.

Targeting endoplasmic reticulum stress-induced lymphatic dysfunction for mitigating bisphosphonate-related osteonecrosis.

Clin Transl Med. 2024 Nov;14(11):e70082. doi: 10.1002/ctm2.70082.

Chimeric antigen receptor dendritic cells targeted delivery of a single tumoricidal factor for cancer immunotherapy.

Cancer Immunol Immunother. 2024 Aug 6;73(10):203. doi: 10.1007/s00262-024-03788-1.

Osteoporosis: interferon-gamma-mediated bone remodeling in osteoimmunology.

Front Immunol. 2024 May 16;15:1396122. doi: 10.3389/fimmu.2024.1396122. eCollection 2024.

Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review.

Osteoporos Int. 2024 Aug;35(8):1337-1358. doi: 10.1007/s00198-024-07059-8. Epub 2024 Apr 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Bisphosphonates for osteoporosis.

作者信息

Favus Murray J

机构信息

Department of Medicine, University of Chicago, Chicago, IL 60637, USA.

出版信息

N Engl J Med. 2010 Nov 18;363(21):2027-35. doi: 10.1056/NEJMct1004903.

DOI:10.1056/NEJMct1004903

PMID:21083387

Abstract

摘要

相似文献

Bisphosphonates for osteoporosis.

N Engl J Med. 2010 Nov 18;363(21):2027-35. doi: 10.1056/NEJMct1004903.

[New bone density conservation agents for osteoporosis under research and development: Minodronic acid].

Nihon Rinsho. 2007 Nov 28;65 Suppl 9:417-20.

Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis.

Curr Med Res Opin. 2010 Nov;26(11):2553-63. doi: 10.1185/03007995.2010.519658. Epub 2010 Sep 21.

Persistence with bisphosphonate therapy in older people.

J Am Geriatr Soc. 2006 Jun;54(6):1015-6. doi: 10.1111/j.1532-5415.2006.00758.x.

In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?

J Okla State Med Assoc. 2010 Aug;103(8):374-5.

Bisphosphonates for osteoporosis--where do we go from here?

N Engl J Med. 2012 May 31;366(22):2048-51. doi: 10.1056/NEJMp1202619. Epub 2012 May 9.

[Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].

Clin Calcium. 2007 Jul;17(7):1090-6.

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

Curr Med Res Opin. 2006 May;22(5):919-28. doi: 10.1185/030079906X100276.

Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.

Prescrire Int. 2009 Dec;18(104):247.

Emerging issues with bisphosphonates.

Rheum Dis Clin North Am. 2006 Nov;32(4):691-702, vi. doi: 10.1016/j.rdc.2006.08.002.

引用本文的文献

Long-term bisphosphonate use and femoral morphological changes in osteoporosis patients: a retrospective cohort study.

Eur J Med Res. 2025 Jul 1;30(1):536. doi: 10.1186/s40001-025-02764-4.

Effect of recombinant human parathyroid hormone and zoledronic acid on osteoblast gene expression using multifaceted approach: An in vitro study.

Indian J Pharmacol. 2025 Mar 1;57(2):69-76. doi: 10.4103/ijp.ijp_582_23. Epub 2025 Jun 13.

Sympathetic cholinergic nerve fibres promote BMSC differentiation into osteoblasts via NRTN secretion: a potential treatment for osteoporosis.

J Orthop Surg Res. 2025 Jun 5;20(1):571. doi: 10.1186/s13018-025-05944-4.

Molecular mechanisms and treatment strategies for estrogen deficiency-related and glucocorticoid-induced osteoporosis: a comprehensive review.

Inflammopharmacology. 2025 Apr 28. doi: 10.1007/s10787-025-01749-3.

Optimizing bone health with bisphosphonate therapies in pediatric osteogenesis imperfecta: a network meta-analysis of randomized trials.

Arch Osteoporos. 2025 Mar 6;20(1):33. doi: 10.1007/s11657-025-01515-6.

Towards Optimal Automated Ga-Radiolabeling Conditions of the DOTA-Bisphosphonate BPAMD Without Pre-Purification of the Generator Eluate.

J Labelled Comp Radiopharm. 2024 Dec;67(14):441-453. doi: 10.1002/jlcr.4128. Epub 2024 Nov 20.

Targeting endoplasmic reticulum stress-induced lymphatic dysfunction for mitigating bisphosphonate-related osteonecrosis.

Clin Transl Med. 2024 Nov;14(11):e70082. doi: 10.1002/ctm2.70082.

Chimeric antigen receptor dendritic cells targeted delivery of a single tumoricidal factor for cancer immunotherapy.

Cancer Immunol Immunother. 2024 Aug 6;73(10):203. doi: 10.1007/s00262-024-03788-1.

Osteoporosis: interferon-gamma-mediated bone remodeling in osteoimmunology.

Front Immunol. 2024 May 16;15:1396122. doi: 10.3389/fimmu.2024.1396122. eCollection 2024.

Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review.

Osteoporos Int. 2024 Aug;35(8):1337-1358. doi: 10.1007/s00198-024-07059-8. Epub 2024 Apr 8.